A
Adrian Alegre
Researcher at Hospital Universitario La Paz
Publications - 151
Citations - 5786
Adrian Alegre is an academic researcher from Hospital Universitario La Paz. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 36, co-authored 133 publications receiving 5002 citations. Previous affiliations of Adrian Alegre include University of Salamanca.
Papers
More filters
Journal ArticleDOI
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesús F. San Miguel,Jesús F. San Miguel,Katja Weisel,Philippe Moreau,Martha Q. Lacy,Kijoung Song,Michel Delforge,Lionel Karlin,Hartmut Goldschmidt,Anne Banos,Albert Oriol,Adrian Alegre,Christopher T. Chen,Michele Cavo,Laurent Garderet,Valentina Ivanova,Joaquin Martinez-Lopez,Andrew R. Belch,Antonio Palumbo,Steve Schey,Pieter Sonneveld,Xiaoyan Yu,Lars Sternas,Christian Jacques,Mohamed H. Zaki,Meletios A. Dimopoulos +25 more
TL;DR: Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients withRefractory or relapsed and refractory multiple myeloma.
Journal ArticleDOI
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Laura Rosiñol,Albert Oriol,Ana Isabel Teruel,D. Hernández,Javier López-Jiménez,Javier de la Rubia,Miquel Granell,Joan Besalduch,Luis Palomera,Yolanda González,Maria Asunción Etxebeste,Joaquín Díaz-Mediavilla,Miguel T. Hernandez,Felipe de Arriba,Norma C. Gutiérrez,Maria Luisa Martin-Ramos,María Teresa Cibeira,Maria-Victoria Mateos,Joaquín Parra Martínez,Adrian Alegre,Juan José Lahuerta,Jesús F. San Miguel,Joan Bladé,Grupo Español de Mieloma +23 more
TL;DR: VTD resulted in a higher pre- and posttransplantation CR rate and in a significantly longer PFS although it was not able to overcome the poor prognosis of high-risk cytogenetics.
Journal ArticleDOI
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal,Paul G. Richardson,S. Vincent Rajkumar,Jesús F. San-Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Sandrine Macé,Kathryn P. Corzo,Frank Campana,Solenn Le-Guennec,Franck Dubin,Kenneth C. Anderson,Vincent Rajkumar,Simon J. Harrison,Wojt Janowski,Ian Kerridge,Andrew Spencer,Michel Delforge,Karel Fostier,Philip Vlummens,Ka Lung Wu,Richard Leblanc,Michel Pavic,Michael Sebag,Roman Hájek,Vladimir Maisnar,Ludek Pour,Henrik Gregersen,Lotfi Benbouker,Denis Caillot,Martine Escoffre-Barbe,Thierry Facon,Laurent Frenzel,Cyrille Hulin,Lionel Karlin,Brigitte Kolb,Brigitte Pegourie,Aurore Perrot,Mourad Tiab,Laure Vincent,Dietger Niederwieser,Achilles Anagnostopoulos,Sosana Delimpasi,Marie Christine Kyrtsonis,Anargyros Symeonidis,Árpád Illés,Gabor Mikala,Zsolt Nagy,Sara Bringen,Paolo Corradini,Ciceri Fabio,Roberto M. Lemoli,Anna Marina Liberati,Chiara Nozzoli,Renato Zambello,Shinsuke Iida,Takashi Ikeda,Satoshi Iyama,Morio Matsumoto,Chihiro Shimazaki,Kazutaka Sunami,Kenshi Suzuki,Michihiro Uchiyama,Youngil Koh,Ki-Hyun Kim,Jae Hoon Lee,Chang-Ki Min,Hillary Blacklock,Hugh Goodman,AJ Neylon,David Simpson,Sebastian Grosicki,Artur Jurczyszyn,Adam Walter-Croneck,Krzysztof Warzocha,Luis Araujo,Claudia Moreira,Vadim A Doronin,Larisa P. Mendeleeva,Vladimir I. Vorobyev,Andrej Vranovsky,Adrian Alegre,Mercedes Gironella,Marta Sonia Gonzalez Perez,Carmen Montes,Enrique M. Ocio,Paula Rodriguez,Mats Hardling,Birgitta Lauri,Ming Chung Wang,Su Peng Yeh,Mutlu Arat,Fatih Demirkan,Zafer Gulbas,Sevgi Kalayoglu Besisik,Ihsan Karadogan,Tulin Tuglular,Ali Ünal,Filiz Vural,Jonathan Sive,Matthew Streetly,Kwee Yong,Jason Tache +111 more
TL;DR: The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomidine and dexAMethas one in patients with relapsed and refractory multiple myeloma.
Journal ArticleDOI
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan José Lahuerta,Maria-Victoria Mateos,Joaquin Martinez-Lopez,Laura Rosiñol,Anna Sureda,Javier de la Rubia,José García-Laraña,Rafael Martínez-Martínez,Miguel T. Hernández-García,Dolores Carrera,Joan Besalduch,Felipe de Arriba,Jose Maria Ribera,Lourdes Escoda,Belén Hernández-Ruiz,Javier García-Frade,Concepción Rivas-González,Adrian Alegre,Joan Bladé,Jesús F. San Miguel +19 more
TL;DR: Quality of response post-transplantation, notably CR, is significantly associated with EFS and OS prolongation in newly diagnosed patients with MM.
Journal ArticleDOI
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva,Norma C. Gutiérrez,Laura Rosiñol,María-Belén Vidriales,María-Angeles Montalbán,Joaquin Martinez-Lopez,Maria-Victoria Mateos,MT Cibeira,Lourdes Cordón,Albert Oriol,María-José Terol,María-Asunción Echeveste,Raquel de Paz,Felipe de Arriba,Luis Palomera,Javier de la Rubia,Joaquín Díaz-Mediavilla,Anna Sureda,Ana Gorosquieta,Adrian Alegre,Alejandro Martín,Miguel T. Hernandez,Juan José Lahuerta,Joan Bladé,Jesús F. San Miguel +24 more
TL;DR: Which prognostic markers can predict unsustained CR in a series of 241 patients in CR at day +100 after HDT/ASCT who were enrolled in the Spanish GEM2000 and GEM2005 trials are investigated.